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MaTeam-based cardiovascular care, including the use of clinical pharmacists, can efﬁciently deliver high-quality care. This
Joint Council Perspectives paper from the Cardiovascular Team and Prevention Councils of the American College of
Cardiology provides background information on the clinical pharmacist’s role, training, certiﬁcation, and potential utili-
zation in a variety of practice models. Selected systematic reviews and meta-analyses, highlighting the beneﬁt of clinical
pharmacy services, are summarized. Clinical pharmacists have a substantial effect in a wide variety of roles in inpatient
and ambulatory settings, largely through optimization of drug use, avoidance of adverse drug events, and transitional
care activities focusing on medication reconciliation and patient education. Expansion of clinical pharmacy services is
often impeded by policy, legislation, and compensation barriers. Multidisciplinary organizations, including the American
College of Cardiology, should support efforts to overcome these barriers, allowing pharmacists to deliver high-quality
patient care to the full extent of their education and training. (J Am Coll Cardiol 2015;66:2129–39)
© 2015 by the American College of Cardiology Foundation.T he American College of Cardiology (ACC)Board of Trustees and Strategic Plan endorseteam-based care as a means to address the
growing cardiovascular disease (CVD) epidemic
(1,2). With a critical shortage of cardiologists, it is
important that collaboration is developed with
nonphysician providers, including clinical pharma-
cists, as an efﬁcient and cost-effective means to
improve patient outcomes. As with other qualiﬁed
nonphysician practitioners, clinical pharmacists are
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2130medication-related adverse events and error,
ﬁnancial waste related to these events can be
decreased and patient outcomes improved
(6,7). In addition, patients with CVD are often
underprescribed critical, evidence-based
therapies for a variety of reasons (8,9). Clin-
ical pharmacists are pharmacists who,
through advanced training, experiences,
and/or certiﬁcation requirements for licen-
sure as a general pharmacist, have the skills
and knowledge to provide clinical pharmacy
services (CPS) to the health care team and
patients. CPS includes, but is not limited to,
complex medication management, transi-
tional care related to medications, and pa-tient or clinician medication education (10). A
summary of CPS is included in the Central Illustration,
demonstrating that the clinical pharmacist may
operate on a patient-speciﬁc, facility, or global level
to achieve optimal medication outcomes. The Amer-
ican College of Clinical Pharmacy (ACCP) deﬁnes CPS
as, “a health sciences discipline in which pharmacists
provide patient care that optimizes medication ther-
apy and promotes health, wellness, and disease pre-
vention” (11). Clinical pharmacists also play a pivotal
role in ensuring medication safety, either through
speciﬁc medication interventions or in designing
macroprocesses to reduce the medication-related risk
of error. In the MEDAP (Medication Error Detection,
Amelioration, and Prevention) study, an observa-
tional analysis of clinical pharmacists engaged in
patient safety initiatives, cardiovascular drugs
comprised the third most-commonly prescribed class
of medications resulting in errors that required
pharmacist intervention (12). Clinical pharmacists
are uniquely positioned to address medication
safety, due to their intimate understanding of the
medication-use process and clinical pharmacology.
To maximize the role of the clinical pharmacist, the
care team will beneﬁt from understanding the
training, development, utilization, and potential
value of the clinical pharmacist in the cardiovascular
care team. This paper will provide background infor-
mation on clinical pharmacists’ education, training,
credentialing, and practice models in a variety of
settings; it will also discuss collaborative practice
opportunities for integrating clinical pharmacists into
a team-based care model.
TRAINING AND CERTIFICATION
Figure 1 depicts the typical training pathway of a
clinical pharmacist working in cardiovascular prac-
tice. There are currently 134 schools and colleges ofpharmacy in the United States, a number that con-
tinues to grow (13). Pharmacy school training is pre-
ceded by a minimum of 2 years of undergraduate
coursework, although many students have completed
a bachelor’s degree. Most pharmacy school curricula
consist of 3 years of didactic coursework, followed by
a fourth year of experiential education. The Doctor of
Pharmacy (PharmD) degree is awarded upon gradua-
tion. Curricula must meet the core standards over-
seen by the American College of Pharmaceutical
Education (ACPE), which have been recently updated
(14). Integration of interprofessional education into
curricula is recommended by the ACPE to better
prepare students to provide patient-centered care.
This involves pharmacy students interacting with
medical, nursing, and other health professional stu-
dents at various levels of training in coordinated
educational or patient care activities (14). Introduc-
tory pharmacy practice experiences are completed in
community pharmacy and hospital settings during
the ﬁrst 3 years, whereas advanced pharmacy practice
experiences occur in the ﬁnal year of school. The
ACPE requires that these advanced experiences
involve direct patient care, interactions with pre-
scribers, and the provision of CPS alongside and su-
pervised by clinical pharmacists (14,15).
Post-graduate education and training for a cardio-
vascular clinical pharmacist may differ from that of
pharmacists working in other settings. Following
graduation from an ACPE-accredited school of phar-
macy, approximately 25% of pharmacists choose to
continue their education in the form of either resi-
dency and/or fellowship training. These programs
continue to grow in response to increased demand
(16). A post-graduate year (PGY)-1 pharmacy resi-
dency program is intended to produce pharmacy
practitioners competent in patient-centered care and
pharmacy operational services that can be applied to
any practice setting (17). Individuals desiring more
specialized clinical training in a cardiovascular area
can complete a PGY2 residency. The aim of a PGY2
pharmacy residency in cardiology is to train phar-
macy practitioners in the care of patients with CVD,
both from a prevention and treatment perspective
(18). Cardiology pharmacy residency programs also
train in the conduct of clinical research projects, the
interpretation of cardiovascular biomedical published
data, quality improvement initiatives, leadership and
practice management, teaching and educational
activities, and advocacy for CVD prevention. The
American Society of Health-System Pharmacists
currently lists 29 PGY2 training programs in cardiol-
ogy pharmacy; these programs have collectively
graduated at least 123 graduates since 2007 (19).
CENTRAL ILLUSTRATION Clinical Pharmacists: Their Role in Cardiovascular Disease
CLINICAL
PHARMACIST
PATIENT-SPECIFIC
SERVICES
FACILITY-SPECIFIC
SERVICES
GLOBAL 
SERVICES 
• Patient education
• Drug interaction screening
• Drug therapy monitoring
• Drug and disease management
• Pharmacogenetics
• Drug information
• Pharmacokinetic/
pharmacodynamic dosing
• Collaborative practice agreements
• Protocol, guideline, and policy 
development and review
• Research
• Core measure and quality 
improvement initiatives
• Formulary management and 
• Medication safety
• Governmental and societal 
committees and agencies
• Societal guideline
and policy development
• Legal consultations
• Public health initiatives
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The various roles clinical pharmacists perform in both inpatient and outpatient settings are depicted. A clinical pharmacist or team of clinical
pharmacists may perform a variety of patient-speciﬁc functions related to medications. Clinical pharmacists often lead facility-level initiatives
and even global initiatives toward improving and optimizing systems of medication use.
FIGURE 1 Education and Training of a Clinical Pharmacist in a Cardiology Practice
Prerequisite
Training
(2 years
minimum)
Doctor of Pharmacy
Degree
(4–year program)
Postgraduate Year
(PGY)–1
Pharmacy Practice
Residency
(1 year)
Clinical Research
Fellowship
Board Certification
and
Multidisciplinary
Credentialing
Postgraduate Year (PGY)–2
Cardiology Residency
(inpatient/outpatient
focus)
(1 year)
Postgraduate Year (PGY)–2
Ambulatory Care
Residency
(outpatient focus)
(1 year)
The most traditional routes to practice as a clinical pharmacist in cardiology are depicted. Participants complete a Doctor of Pharmacy program and then
1 or 2 years of post-graduate residency training (post-graduate year [PGY]-1 and -2). Ambulatory care–trained pharmacists are focused on outpatient care
and would mostly focus on modifying chronic cardiovascular risk with pharmacotherapy with a broad understanding of pharmacotherapeutic management
of chronic disease. Cardiology-trained clinical pharmacists are adaptable to a wide variety of cardiology practice settings, including inpatient and outpatient
practices, which would provide a greater understanding of patient care in the cardiovascular continuum. Pharmacists may also complete a clinical research
fellowship, designed to train the participant to be an independent research investigator.
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2132A clinical research fellowship is a highly individu-
alized post-graduate program designed to train
pharmacists to become independent investigators
(Figure 1). Its aim is for graduates to develop compe-
tency in all aspects of the scientiﬁc research process,
from hypothesis generation to paper preparation and
publication. Fellowships are offered through a variety
of settings, including schools and colleges of phar-
macy, the pharmaceutical industry, and academic
health centers. Like PGY2 residency programs, fel-
lowships are often focused on a speciﬁc area of
pharmacy practice. The ACCP offers peer-review
designation for qualiﬁed programs, and lists 6
fellowship programs with a primary or secondary
specialty of cardiology.
Beyond formal didactic education and clinical
training, pharmacy has mechanisms to ensure that
entry-level practitioners have met the minimum
qualiﬁcations through certiﬁcation (20). For most
health care professionals, this initial step in ensuring
qualiﬁcation to practice is through licensure.
Beyond licensure, certiﬁcation for the pharmacist
is different from that of physicians and nonphy-
sician practitioners. For pharmacists, certiﬁca-
tion is voluntary, consisting of pharmacist-only and
multidisciplinary certiﬁcations (21). One of the major
organizations with a long history of awarding specialty
certiﬁcation credentials to pharmacists is the Board of
Pharmacy Specialties (BPS) (11). Themission of the BPS
is to recognize pharmacy specialty practice and certify
pharmacists’ knowledge and skill to practice in the
areas of nuclear, nutrition support, oncology, phar-
macotherapy, ambulatory care, pediatrics, criticalExamples of Multidisciplinary Certiﬁcations for Pharmacists
dentialing Organization Credential
ertiﬁcation Board for
agulation Providers
Certiﬁed Anticoagulation Care
Provider (CACP)
Pro
sthma Educator
ation Board
Certiﬁed Asthma Educator (AE-C) Pro
ertiﬁcation Board for
es Educators
Certiﬁed Diabetes Educator (CDE) De
ion Council For Clinical
ogy
Clinical Lipid Specialist (CLS) Pro
Board of Applied
logy
Diplomat of the American Board of
Applied Toxicology (DABAT)
Pa
th permission from Saseen et al. (24).care, and psychiatric pharmacy; cardiology specialty
certiﬁcation is also being considered. Eligibility for
certiﬁcation through BPS requires pharmacy licensure,
and documentation of 3 years of experience within a
practice area or completion of a PGY1 and/or PGY2
residency, plus successful passing of a standardized,
written examination. Through the BPS, pharmacists
can also obtain certiﬁcation in certain areas of
subspecialization, including added qualiﬁcations in car-
diology (22), which involves participation in specialty-
related practice, teaching, research, and scholarship.
As of 2013, more than 19,000 pharmacists have been
credentialed by the BPS, with over 100 practitioners
receiving added qualiﬁcations in cardiology (23).
Pharmacists may also obtain more broad-based,
multidisciplinary certiﬁcations covering various
areas of CVD. These types of certiﬁcations as-
sess health care-related competency for an array
of different professions (e.g., nurses, nurse practi-
tioners, and physician assistants) (24). Eligibility
requirements for each of these vary, but are typi-
cally dependent upon documentation of practice
and completion of an examination. Table 1 provides
examples of multidisciplinary credentials for phar-
macists in terms of the credentialing organization
and intended scope of professional practice (24,25).
PHARMACIST PRACTICE MODELS AND
CLINICAL ACTIVITIES
The beneﬁts of CPS in federal, nonfederal, hospital,
clinic, managed care, and other community settings
have been extensively documented (26). However,Intended Scope of the Credentialed Professional
vide care to patients receiving anticoagulation therapy. Clinical care
includes systematic, organized, and ongoing patient education and
therapeutic management in the inpatient and/or outpatient setting.
vide care and expertise in teaching, educating, and counseling
individuals with asthma and their families in the knowledge and skills
necessary to minimize the effect of asthma on their quality of life. A
primary job responsibility is the provision of asthma coordination and
counseling services.
ﬁned roles as diabetes educators, not for those who may perform some
diabetes-related functions as part of, or in the course of, other usual and
customary duties.
vide specialized care to patients with dyslipidemia and related
cardiometabolic conditions.
rticipate in all aspects of toxicology, including the design and
interpretation of safety studies for product development; review
and interpretation of such studies for regulatory compliance; basic and
applied research into toxic effects, mechanisms of toxic action,
toxicokinetics, and toxicodynamics; and education of undergraduates,
professional and graduate students, and the public in the science of
toxicology through courses, legal cases, and media interactions.
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2133there is no uniﬁed national model of CPS; practices
may vary across institutions. CPS have been associ-
ated with decreased costs of care, hospital mortality,
drug costs, length of stay, and medication error rates
(27–29). The Institute of Medicine recognizes that the
pharmacist-physician-patient collaboration improves
medication safety (30). Interacting with the health
care team on inpatient rounds, interviewing patients
and family, selecting and reconciling medications,
performing dose titration, assisting with insurance
coverage, and providing patient discharge counseling
and follow-up are among the many efforts by clinical
pharmacists that have resulted in improved outcomes
in the inpatient setting (31–33). Interacting with a
pharmacist in the inpatient setting has also helped
improve post-discharge medication adherence
(31,34), reduce adverse drug reactions and medication
errors (31), and shorten hospital length of stay (31).
Several reviews and meta-analyses have demon-
strated the effect of CPS in cardiovascular patients
(Table 2). Clinical pharmacists have helped to
improve CVD risk factor management (35–39). The
results are consistent with other studies that showed
improvements in CVD risk factor management by
pharmacists in primary care ofﬁces (40,41), cardiol-
ogy practices (42,43), a managed care organization
(44), and a chain pharmacy setting (45). In general,
the addition of inpatient and outpatient CPS resulted
in improved care, with no evidence of harm.
Clinical pharmacists have shown a particular effect
in patients with heart failure. For inpatient services,
Gattis et al. (46), in a single-center, randomized
clinical trial of 180 patients with heart failure,
measured the effect of pharmacist participation in
heart failure rounds. The composite of all-cause
mortality and heart failure events was signiﬁcantly
lower after 6 months in the team with pharmacist
participation (4 events vs. 16 events [all-cause mor-
tality or heart failure]; p ¼ 0.005). Pharmacists’ care
of inpatients and outpatients with heart failure has
resulted in decreased hospitalizations (47,48) and
readmissions (48). The Heart Failure Society of
America recently coauthored a joint opinion paper
with the ACCP Cardiology Practice and Research
Network that outlined and supported roles for phar-
macists in multidisciplinary heart failure teams (10).
Whereas many patient care services by clinical
pharmacists can be performed concurrently with or
complementary to physician practice (e.g., medica-
tion reviews, patient education and counseling, dis-
ease screening, referral, among others), clinical
pharmacists may also perform independent direct
medication management through a collaborative
practice agreement (CPA) that expands the depth andbreadth of services the pharmacist can provide. CPAs
that include a pharmacist can help alleviate some of
the demand for physician-provided care. CPAs create
a formal relationship between physicians and phar-
macists and deﬁne patient care functions (e.g., pa-
tient assessments, counseling, and referrals; ordering
laboratory tests; administering drugs; and selecting,
initiating, monitoring, continuing, and adjusting drug
regimens) that a pharmacist can autonomously pro-
vide within the context of a protocol. CPAs are
not new; federal pharmacists have collaboratively
managed disease through medication use, cognitive
services, and CPS for over 40 years (49). When a CPA
is in place, a licensed health care professional makes a
diagnosis and maintains ongoing supervision of pa-
tient care. Currently, 46 states and the District of
Columbia allow for some form of CPAs. CPA pro-
visions vary greatly from state to state with respect
to the extent of the pharmacists’ authorized ser-
vices, limitations on practice sites and health con-
ditions, authority to order laboratory tests, and
requirements for pharmacist participation (e.g., cer-
tiﬁcation, training, or enhanced licensure require-
ments or designations).
Kaiser Permanente of Colorado’s collaborative
practice model uses nurses and clinical pharmacists
in direct patient care roles, guided by a physician.
This model reduced all-cause mortality (adjusted
hazard ratio: 0.24; 95% conﬁdence interval: 0.20 to
0.29; p < 0.001) or coronary heart disease–related
mortality (adjusted hazard ratio: 0.27; 95% conﬁ-
dence interval: 0.22 to 0.34; p < 0.001) in patients
with coronary artery disease who were followed in
the program for more than 3 years. Patients
enrolled <90 days (“early exposure”) after their cor-
onary event had lower all-cause mortality over a
10-year follow-up period compared with other groups
of patients not enrolled within 90 days post-event
(4.7% early vs. 8.6% delayed, 16.4% intermittent,
and 46.9% none; p < 0.001) (50). Patients usually
enrolled in the nurse-managed cardiac rehabilitation
program within 3 to 6 months after discharge for a
coronary event, followed by enrollment in the
pharmacist-managed program. The goals were to in-
crease use of evidence-based therapies, help monitor
and control diseases that increase CVD risk (e.g., hy-
pertension, hyperlipidemia, diabetes, and abuse),
and provide information to patients and other team
members (51). Ripley et al. (52) describe in detail a
similar practice model that uses cardiologist–clinical
pharmacist collaboration in the long-term manage-
ment of patients with CVD in both an academic
faculty-based practice and a private sector specialty
clinic. The practice model is structured around a
TABLE 2 Selected Systematic Reviews and Meta-Analyses of the Effect of Pharmacist Services on Cardiovascular Patient Care
Citation Methods Results Authors’ Conclusions
Carter et al. (35)
Purpose: to determine the
potency of interventions
for BP involving nurses
or pharmacists.
MEDLINE search (1970 to
February 5, 2009)
Inclusion: controlled clinical trials involving
a nurse or pharmacist intervention.
Determined mean reductions in SBP
and DBP
37 studies
Improved BP (8.75/3.60 mm Hg): education on
BP medications.
Associated with signiﬁcant SBP reductions:
pharmacist recommended medication to
physician; counseling on lifestyle modiﬁcation;
pharmacist performed
the intervention; use of a treatment algorithm;
completion of a drug proﬁle and/or medication
history).
Associated with signiﬁcant DBP reductions: referral
to a specialist; providing patient education
about BP medications, completion of a drug
proﬁle and/or medication history; pharmacist
performed the intervention.
The nursing, pharmacist, and community pharmacist
studies lowered BP; the amounts lowered were
not statistically different.
Team-based care, including a pharmacist
or nurse, was associated with
improved BP control.
Limitations: studies with short-term
interventions and interventions
performed outside of the clinic were
less potent in efﬁcacy.
Chisholm-Burns et al. (36)
Purpose: to examine effects
of pharmacist-provided
direct patient care on
therapeutic, safety, and
humanistic outcomes.
NLM PubMed; Ovid/MEDLINE;
ABI/INFORM;
Health Business Fulltext Elite; Academic
Search Complete;
International Pharmaceutical Abstracts;
PsycINFO; Cochrane
Database of Systematic Reviews;
National Guideline
Clearinghouse; Database of Abstracts
of Reviews of Effects;
ClinicalTrials.gov; LexisNexis Academic
Universe; and Google
Scholar (start to January 2009)
Inclusion: RCTs with pharmacist
involvement in direct patient care and
evaluated patient-related outcomes
reported (therapeutic, safety, or
humanistic) (start to November 2010)
298 studies
Mean difference between the pharmacist group and
the comparison group:
 LDL-C: 6.3 mg/dl (95% CI: 6.5 to
6.0 mg/dl)
 SBP: 7.8 mm Hg (95% CI: 9.7 to
5.8 mm Hg)
 DBP: 2.9 mm Hg (95% CI: 3.8 to
2.0 mm Hg)
 HbA1c: 1.8% (SD ¼ 0.5; 95% CI:
2.7 to minus;0.9).
Medication adherence, patient knowledge, and
quality of life general health meta-analyses were
signiﬁcant (p < 0.05)
Pharmacist services improved patient
care, with no evidence of harm.
Limitations: studies with short-term
interventions were less likely to be
successful. Not all studies were likely
powered to detect signiﬁcant
differences. Implementation of
interventions was not uniform and
heterogeneous activities were
applied.
Santschi et al (37)
Purpose: to determine the
effect of pharmacist
care on the
management of CVD
risk factors among
outpatients.
MEDLINE, EMBASE, CINAHL, Cochrane
Central Register of Controlled Trials
(start to November 2010)
Inclusion: RCTs involving
pharmacist care interventions among
outpatients with CVD risk factors.
Determined mean changes in BP, total
cholesterol, LDL-C, and proportion of
smokers using random effects models
30 studies (11,765 patients)
Compared with usual care, pharmacist care was
associated with signiﬁcant reductions in:
 SBP/DBP: 19 studies with 10,479 patients;
8.1 mm Hg (95% CI: 10.2 to 5.9 mm Hg)/
3.8 mm Hg (95% CI: 5.3 to 2.3 mm Hg)
 Total cholesterol: 9 studies with 1,121
patients; 17.4 mg/l (95% CI: 25.5 to
9.2 mg/l)
 LDL-C: 7 studies with 924 patients; 13.4 mg/
l (95% CI: 23.0 to 3.8 mg/l)
 Risk of smoking: 2 studies with 196 patients;
relative risk: 0.77 (95% CI: 0.67 to 0.89).
Pharmacists improved CVD risk factor
management among outpatients.
Limitations: types of interventions
performed to affect BP, LDL-C, and
so forth were not uniform.
Santschi et al. (38)
Purpose: to assess the
effect of pharmacist
care on CVD risk factors
in outpatients with
diabetes.
MEDLINE, EMBASE, CINAHL, Cochrane
Central Register of Controlled Trials
(start to March 2012)
Inclusion: RCTs involving pharmacist care
interventions among outpatients with
diabetes and CVD risk factors.
Determined mean changes in BP, total
cholesterol, LDL-C, and BMI using
random effects models
15 RCTs (9,111 outpatients)
Compared with usual care, pharmacist care was
associated with signiﬁcant reductions in:
 SBP: 12 studies with 1,894 patients;
26.2 mm Hg (95% CI: 27.8 to 24.6 mm Hg)
 DBP: 9 studies with 1,496 patients;
24.5 mm Hg (95% CI: 26.2 to 22.8 mm Hg)
 Total cholesterol: 8 studies with 1,280 pa-
tients; 215.2 mg/dl (95% CI: 224.7 to
25.7 mg/dl)
 LDL-C: 9 studies with 8,084 patients; 211.7
mg/dl (95% CI: 215.8 to 27.6 mg/dl)
 BMI: 5 studies with 751 patients; 20.9 kg/m2
(95% CI: 21.7 to 20.1 kg/m2)
Pharmacists improved CVD risk factor
management in outpatients with
diabetes.
Limitations: types of interventions
performed to affect cardiovascular
risk were not uniform.
Continued on the next page
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2134deﬁned scope-of-practice agreement between the
cardiologists and pharmacists (52). Pharmacist in-
volvement has also been demonstrated to improve
medication adherence. A recent study by Ho et al. (53)
evaluated a multifaceted intervention to improvemedication adherence involving pharmacist-led
medication reconciliation, education, and collabora-
tive care between the pharmacists and physicians in
the Veterans Affairs health system. Patients ran-
domized to the intervention had greater adherence
TABLE 2 Continued
Citation Methods Results Authors’ Conclusions
Santschi et al. (39)
Purpose: to assess the
effect of pharmacist
interventions on BP and
identify potential
determinants of
heterogeneity.
MEDLINE, EMBASE, CINAHL, Cochrane
Central Register of Controlled Trials (start
to March 2012)
Inclusion: RCTs involving pharmacist care
interventions among outpatients with
or without diabetes. Determined mean
changes in BP using random effects
models
39 RCTs (14,224 outpatients)
Compared with usual care, pharmacist care was
associated with signiﬁcant reductions in:
 SBP: 7.6 mm Hg (95% CI: 9.0 to 6.3
mm Hg; I2 ¼ 67%)
 DBP: 3.9 mm Hg (95% CI: 5.1 to 2.8;
I2 ¼ 83% mm Hg)
Pharmacists improved BP management
in outpatients.
Limitations: types of interventions
performed to affect BP were not
uniform.
Koshman et al. (47) PubMed, MEDLINE, EMBASE, International
Pharmaceutical Abstracts, Web of
Science, Scopus, Dissertation Abstracts,
CINAHL, Pascal, Cochrane Central
Register of Controlled Trials (start to
August 2007)
Inclusion: RCTs evaluating the effect of
pharmacist care activities on patients
with HF in both inpatient and
outpatient settings
12 RCTs (2,060 patients)
Pharmacist care reduced:
 All-cause hospitalizations: 11 studies with
2,026 patients (OR: 0.71; 95% CI: 0.54 to
0.94)
 HF hospitalizations: 11 studies with 1,977 pa-
tients; (OR: 0.69; 95% CI: 0.51 to 0.94)
Pharmacist collaborative care led to greater re-
ductions in the rate of HF hospitalizations (OR:
0.42; 95% CI: 0.24 to 0.74) than pharmacist-
directed care (OR: 0.89; 95% CI: 0.68 to 1.17).
Pharmacist care in the treatment of
patients with HF greatly reduces the
risk of all-cause and HF
hospitalizations
Limitations: mortality was not affected,
likely due to the small sample size of
many studies included. Follow-up
was limited to #6 months. The
interventions applied were not
uniform.
BMI ¼ body mass index; BP ¼ blood pressure; CI ¼ conﬁdence interval; CVD ¼ cardiovascular disease; DBP ¼ diastolic blood pressure; HbA1c ¼ hemoglobin A1c; HF ¼ heart failure; LDL-C ¼ low-density
lipoprotein cholesterol; OR ¼ odds ratio; RCT ¼ randomized controlled trial; SBP ¼ systolic blood pressure.
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2135to cardiovascular medications (clopidogrel, beta-
blockers, statins, and angiotensin inhibitors) than
the usual care group (89.3% vs. 73.9%; p ¼ 0.003) (53).
SCOPE OF PRACTICE
In 2012, a consortium of stakeholders identiﬁed
effective policies, practices, and barriers to expand-
ing the role of pharmacists in delivering patient care
services and entering into CPAs. The group ack-
nowledged that broad access to patient care services
delivered by pharmacists is limited by scope of prac-
tice acts, state boards of pharmacy, medicine regula-
tions, and compensation barriers. Recognizing that
physician-pharmacist CPAs may help alleviate some
of the gaps in health care, the consortium proposed
strategies for expanding pharmacists’ patient care
services through team-based care and CPAs (54,55).
The Centers for Disease Control and Prevention and
the American Pharmacists Association Foundation
developed a toolkit for creating physician-pharmacist
CPAs (56).
CPAs may also exist in hospitals. In 2012, The
Centers for Medicare & Medicaid Services expanded
the concept of medical staff to allow hospitals the
ﬂexibility to include pharmacists as eligible candi-
dates with privileges to practice in the hospital in
accordance with state law. The rule gives practi-
tioners in states that allow pharmacists to enter into
CPAs more involvement in patient care. As a result,
pharmacists will undergo the credentialing or priv-
ileging process established by the workplace (57).These CPAs may exist to provide speciﬁc services
in patients with CVD, such as anticoagulation
adjustment and monitoring, insulin management,
and smoking cessation, among other potential appli-
cations that may beneﬁt a cardiology practice.
ADVOCACY AND PUBLIC HEALTH
The public health role of the clinical pharmacist has
been evolving as clinical practice opportunities have
expanded. Starting with the Department of Health and
Human Services “Healthy People” initiatives, and
continuing with the current “Million Hearts” Initiative
to prevent 1 million heart attacks and strokes by 2017,
pharmacists have been sought out for their potential
contributions to these national campaigns. Pharma-
cists have a unique role in community-based public
health initiatives due to the sheer number of neigh-
borhood pharmacies, which provide easy access to care
for patients. Although evidence-based drug therapies
and government educational campaigns have been
successful in reducing cardiovascular deaths in the
past several decades, much work remains to be done.
The Million Hearts campaign estimated that baseline
aspirin use for high-risk patients is still only 47%, blood
pressure is controlled in only 46%, cholesterol is only
controlled in 33%, and smoking cessation is only 23% at
baseline, all of which are far from their clinical targets
of 70% (58). Pharmacist participation in the campaign
through chain pharmacy corporations has largely tar-
geted enhanced cardiovascular risk screening, as well
as educational efforts (59). Although the speciﬁc effect
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known, the provision of CPS appears to be a common-
ality amongst several high-performing organizations
contributing to the campaign (60). These roles may
include direct patient management of blood pressure
to treatment goal, monitoring and encouraging medi-
cation adherence, disease/medication education for
patients, and support for physician staff. Pharmacists
also participate signiﬁcantly with registry or payor-
directed efforts to systematically improve quality
through improved medication use and optimization,
such as the Joint Commission Core Measures. For
example, hospitals employing clinical pharmacists
credentialed in cardiology performed better in car-
diovascular medication-related core measures (61).
Pharmacists, both clinical and general practi-
tioners, play a valuable role in public disease pre-
vention and health promotion through education,
preventive health screenings, and quality assurance.
Education of patients about cardiac risk factors,
methods of risk factor modiﬁcation, and diet and
exercise contributes to reductions of cardiovascular
events and promotes healthy lifestyles (62), including
the promotion of medication adherence (63,64).
Several demonstration projects and innovative prac-
tice settings with pharmacist involvement have yiel-
ded beneﬁcial outcomes. The most notable of these
was the Asheville Project, where pharmacist-
provided education and monitoring positively
affected long-term health outcomes, such as hemo-
globin A1c and serum lipid concentrations, while also
reducing health care costs (65). Ramalho de Oliveira
et al. (64) evaluated 10 years of pharmacy medication
therapy management interventions in a large health
system. Along with cost savings and improved patient
outcomes, patient satisfaction scores were also high.
Targeting of higher cardiac-risk patients by phar-
macists through implementation of quality assur-
ance programs, disease-state management drug
therapy protocols, and health outcomes research
inﬂuences outcomes and decreases the likelihood of
medication errors. Once a diagnosis is made, phar-
macists can assist in chronic disease-state manage-
ment, particularly with medication education and
optimizing medication therapies for a given disease
state.
IMPLICATIONS FOR MEDICAL PRACTICES
The potential for clinical pharmacy services in an
ambulatory or hospital-based practice is vast, as
optimization of medication use requires thorough
evaluation of each aspect of the medication-
use spectrum. At a minimum, having a clinicalpharmacist available to a practice as a consultant to
evaluate medication protocols and guidelines, offer
suggestions for individual patient care through pro-
spective or retrospective review on the basis of
pharmacological principles, and provide medication
education for patients and health care practitioners at
all levels would provide signiﬁcant beneﬁt to a med-
ical practice. Going further, as medication-related
transitional care becomes a prominent goal of
accountable care organizations and other health care
quality organizations, clinical pharmacists could
potentially have a larger role in ensuring that
medication-related transitions are performed safely,
either as direct participants or by directing or
reviewing medication transitional care processes. In
addition, much of complex medication management
(e.g., pharmacological treatment of hypertension,
diabetes, dyslipidemia, and anticoagulation, among
others) could be directly delegated through the use of
CPAs to a clinical pharmacist under the supervision of
an individual practitioner or the medical practice,
enabling greater efﬁciency for physicians and other
providers in seeing patients. The information pro-
vided by Ripley et al. (52) and the ACCP is a valuable
“how-to” for others wanting to implement CPAs in a
physician ofﬁce (52,66). Pharmacists can also play an
important role in improving medication adherence in
at-risk patients, either through direct consultation or
other medication education-related activities.
Although the beneﬁts of utilizing clinical pharma-
cists are bountiful, widespread adoption of this care
model is impeded by the lack of a consistent direct
reimbursement source for these activities. Pharma-
cists are not currently recognized as providers by
the Social Security Act or Centers for Medicare &
Medicaid Services and are, therefore, compensated at
the lowest-level reimbursement code (i.e., level 1
or 99211) in most clinic settings or provided no com-
pensation for activities. The Social Security Act is the
reference point for current and emerging delivery
systems and payment models, so it is important for
pharmacists to be listed in the Social Security Act,
along with other providers. Alternatively, pharma-
cists may utilize incident-to-billing for higher levels
of reimbursement, provided that the medical practice
has the infrastructure to support this model. How-
ever, the comprehensive scope and patient com-
plexity requires that the pharmacists have adequate
and variable time per visit, which precludes patient
volume as a means to generating a sustainable in-
come in the current reimbursement model.
To provide a sustainable platform for the incorpo-
ration of clinical pharmacists in a team-based care
model, more support from themedical community and
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2137changes in legislation are required. The 2011 U.S. Sur-
geon General Report: Improving Patient and Health
System Outcomes through Advanced Pharmacy Prac-
tice publicly supported health care reform that in-
cludes pharmacists providing expanded patient care
services (26). On the basis of the documented beneﬁts
of pharmacist-delivered care in many health care set-
tings, the report recommends that health care leader-
ship and policy makers optimize pharmacists’ roles to
deliver patient-centered care and disease prevention
services in collaboration with physicians or as part of a
health care team. The report further recognizes that
the expansion of pharmacist services is often impeded
due to policy, legislation, and compensation barriers;
it recommends recognizing pharmacists as providers
and allowing appropriate compensation for services
provided.
Several legislative efforts have since been brought
forth, including bills proposed within the last 2 Con-
gresses that are designed to give Medicare beneﬁ-
ciaries in medically underserved communities access
to pharmacist-provided ambulatory services under
Medicare Part B (67). A proposed Medicare program to
provide a separate payment for chronic care man-
agement, for which the physician may also bill for
supervision of clinical staff, may be another pathway
for the utilization of clinical pharmacists (68). Re-
gardless, as “population health” reimbursement
models with bundled payments and accountable care
organizations become more prominent, direct fee-for-
service reimbursement may be less important, as the
ﬁnancial incentives to provide optimal care, while
also reducing preventable harm, are more closely
aligned. Alignment on the basis of quality incentives
can also be encouraged through multidisciplinary
organizational involvement. Some examples of this
are the ACC Surviving MI program (69), a key tenet ofwhich is the involvement of pharmacists in care of
patients with myocardial infarction, and in the Hos-
pital to Home (H2H) Mind Your Meds program, which
features accurate medication reconciliation as a key
metric of success (70).
CONCLUSIONS
Clinical pharmacists, through their unique training
and practice focused onmedication use, are positioned
to serve an important role for patients on the cardio-
vascular care team. Clinical pharmacists currently
engaged with medical practices also make substantial
contributions to practice through the optimization of
drug use and avoidance of preventable adverse drug
events. The ACC advocates team-based care, which
includes clinical pharmacists, as ameans to “transform
care, improve heart health, and helpmeet the demands
of the future.” However, the use of pharmacists is
limited in current care delivery models because phar-
macists are not currently recognized as providers and
are not eligible for payment under Medicare Part B.
With more inclusive legislation, pharmacists could
continue expansion of their roles tomeet the demands,
reduce medication-related costs, and improve quality
of care for cardiac patients in an ever-changing
health care system. Multidisciplinary organizations,
including the ACC, should support efforts to overcome
legislative and compensation barriers so that phar-
macists may be included in health care delivery
models that allow full use of their education and
training to provide high-quality patient care.
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